@inproceedings{inproceedings, title  = {{Dupilumab is effective in children aged 6-11 years with severe atopic Dermatitis (AD) regardless of baseline serum total immunoglobulin E levels}},

 url = {{}},

 year = {{2021}},

 month = {{1}},

 author = {{Cork MJ and Wollenberg A and Siegfried EC and Arkwright PD and Chen Z and Levit NA and Marco AR and Radwan A}},

 volume = {{51}},

 journal = {{CLINICAL AND EXPERIMENTAL ALLERGY}},

 issue = {{12}},

 pages = {{1659-1659}},

 note = {{Accessed on 2024/12/22}}}